Allen Thayakumar Basanthakumar
Senior Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Year:
2026
Year:
2026
Year:
2025
CBFA2T3::GLIS2 fusion positive pediatric acute myeloid leukemia (AML) remains one of the worst prognostic AML subgroups. To uncover innovative targeted therapeutic approaches in this disease subtype we performed genome-scale CRISPR-Cas9 screening that highlighted a strong, selective dependency on JAK2 compared to other types of cancer. Using a doxycycline-inducible JAK2 knockout (KO) system, we validated JAK2 dependency in CBFA2T3::GLIS2 cell lines, observing impaired proliferation in vitro and in vivo and induced apoptosis with JAK2 KO. Both type I (ruxolitinib) and type II (CHZ868) JAK2 inhibitors showed selective in vitro activity in CBFA2T3::GLIS2 positive AML models. To identify resistance and sensitizer mechanisms to JAK2 inhibitors, we used CRISPR-Cas9 ruxolitinib anchor screening in CBFA2T3::GLIS2 AML. sgRNAs targeting negative regulators of the MAPK pathway were enriched in the ruxolitinib-treated cells. Similarly, CBFA2T3::GLIS2 AML sublines grown to resistance under chronic ruxolitinib treatment expressed pathogenic NRAS mutations. Both approaches converged on MAPK pathway activation as a resistance mechanism to ruxolitinib treatment. Combining ruxolitinib with MEK inhibitors showed a synergistic effect in cell lines and patient-derived xenograft (PDX) cells expressing the fusion and in vivo activity in a CBFA2T3::GLIS2 AML PDX, suggesting a potential approach to target this signaling circuitry in this poor outcome AML subtype.
Year:
2025
Pediatric cancers are frequently driven by genomic alterations that result in aberrant transcription factor activity. Here, we used functional genomic screens to identify multiple genes within the transcriptional coactivator Spt-Ada-Gcn5-acetyltransferase (SAGA) complex as selective dependencies for MYCN -amplified neuroblastoma, a disease of dysregulated development driven by an aberrant oncogenic transcriptional program. We characterized the DNA recruitment sites of the SAGA complex in neuroblastoma and the consequences of loss of SAGA complex lysine acetyltransferase (KAT) activity on histone acetylation and gene expression. We demonstrate that loss of SAGA complex KAT activity is associated with reduced MYCN binding on chromatin, suppression of MYC/MYCN gene expression programs, and impaired cell cycle progression. Further, we showed that the SAGA complex is pharmacologically targetable in vitro and in vivo with a KAT2A/KAT2B proteolysis targeting chimeric. Our findings expand our understanding of the histone-modifying complexes that maintain the oncogenic transcriptional state in this disease and suggest therapeutic potential for inhibitors of SAGA KAT activity in MYCN -amplified neuroblastoma.
Year:
2024
Despite advances in therapeutic strategies for patients with AML not eligible for intensive chemotherapy, survival rates for this subset of patients remain particularly poor. Among this group are older adult patients who receive the hypomethylating agents (HMAs) azacitidine or decitabine as frontline therapy. Despite their status as FDA-approved drugs, HMA monotherapy only achieves low response rates in patients with AML and is not a curative treatment. Discovery of novel sensitizers that can be used in combination with HMAs are needed to improve patient outcome. One challenge is that the mechanism by which HMAs are active in AML has been elusive. We deployed genome-wide CRISPR-Cas9 screens using the two standard HMAs (decitabine and azacitidine) and a selective DNMT1 inhibitor (GSK-3680532) to identify novel response and resistance mechanisms to HMAs. Our screens identified well-characterized, as well as unexplored targets, with a strong overlap among the three different drugs. We discovered an enrichment of genes involved in chromatin remodeling and transcriptional regulation, with knockout (KO) of the gene USP48, which encodes a deubiquitinating enzyme, as the top sensitizer in AML cells. We validated USP48 KO in competitive growth and toxicity assays as a selective sensitizer for HMAs in multiple AML cell lines. In contrast, no increased toxicity was seen with other nucleoside analogues or DNA damage inducing agents, such as cytarabine or doxorubicin, suggesting that loss of DNMT1 and the demethylation of DNA is responsible for the observed synergy. To begin to understand which mechanism of HMAs is enhanced through USP48 KO, we utilized cell differentiation and cell death assays. While the loss of USP48 alone did not affect cell growth or viability, the addition of low dose HMA treatment led to a decrease in cell viability with increased DNA damage and induction of apoptosis. In contrast, no differentiation was observed. In vivo, in two independent studies using an orthotopic mouse model of human AML, we found that the AML model with USP48 KO and 7-day treatment with the DNMT1 inhibitor GSK-3680532 had ablated disease burden in the bone marrow (< 0.5% hCD45+ blasts) and prolonged survival. Mice with non-targeting guides or USP48 KO treated with the vehicle control had ~25% hCD45+ blasts, while the DNMT1 inhibitor in the non-targeting control mice showed some antitumor effect (9% hCD45+ blasts). To date, little is known about the direct substrates of USP48. To gain better insight into possible targets of USP48 we used an omics-based approach, generating ubiquitinome, proteome, interactome IP-mass spectrometry and RNA-Seq data. The ubiquitinome data revealed a significant enrichment of H2A variant ubiquitination and enhanced ubiquitination of key proteins involved in the recognition of DNA double-strand breaks (DSB) (Ku70/Ku80 and PRKDC) upon USP48 KO. These findings were confirmed in the interactome data set, where the H2AX core histone complex was among the most enriched CORUM protein complexes. RNA-Seq data showed increased expression of gene sets involved in DNA damage repair and chromatin organization upon USP48 KO, consistent with a cellular response to maintain chromatin stability. Additional genome-scale CRISPR-Cas9 screening of USP48 KO cells with HMA treatment revealed the KO of RNF138, UBE2K and UBE2D3 as rendering resistance to all three drugs. While previous reports showed that USP48 erases BRCA1 ubiquitin sites, ours is the first work linking the RNF138-UBE2K/UBE2D3 ubiquitination machinery to USP48. RNF138, an E3 ubiquitin ligase, is also described to ubiquitinate and displace repair proteins from DSB sites, connecting RNF138 itself to DNA repair pathway choice. Low-throughput validation confirms rescue of HMA + USP48 KO toxicity with the knockout of either RNF138 or its E2 ligases UBE2K/UBE2D3 in AML cells. Taken together our data confirm a role for USP48 as a histone deubiquitinase, influencing the modifi
Year:
2024
Cofactors, many of which are vitamin-derived, are organic molecules with diverse biological functions. They are required for many metabolic pathways and enzymatic reactions, and thus can influence cell proliferation and differentiation. Though the role of vitamins in non-malignant contexts is relatively well characterized, their role in carcinogenesis is not well defined. Here, we sought to molecularly characterize how vitamins contribute to oncogenesis in acute myeloid leukemia (AML). We performed vitamin depletion screens in AML cells using culture medium designed to mimic human plasma. These screens revealed deprivation of riboflavin (Vitamin B2) as detrimental to AML proliferation. Analysis of the Cancer Dependency Map (DepMap) and in vivo CRISPR-Cas9 screens identified the first, rate-limiting enzyme of riboflavin metabolism, riboflavin kinase (RFK), as a hematological cancer dependency. Genetic knockout (KO) of RFK or exogenous depletion of riboflavin in genetically diverse AML cell lines and patient-derived xenograft (PDX) cells induced AML differentiation and apoptosis. Riboflavin depletion was rescued by addition of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), the cofactor products of riboflavin metabolism. We validated that the growth of non-hematological cancer cells was largely unperturbed by exogenous deprivation of riboflavin or RFK KO, highlighting the specificity of this vulnerability in AML. To understand the mechanistic basis of riboflavin dependency in AML, we performed mass spectrometry-based metabolomics studies. Whilst RFK loss dramatically reduced FMN and FAD pools, it also selectively depleted pyrimidine nucleotide species. A subsequent loss-of-function screen using riboflavin restricted culture medium and a metabolism-focused CRISPR-Cas9 library showed that loss of multiple genes encoding purine nucleotide biosynthesis enzymes promoted cell growth in riboflavin-restricted conditions, thereby alleviating the nucleotide imbalance induced by RFK loss. Accordingly, uridine supplementation partially restored proliferation in riboflavin deficient media. Nucleotide imbalance was accompanied by strongly impaired assembly of mitochondrial complex I and II which led to concomitant collapse in oxidative phosphorylation; indeed, loss of respiratory complex I and II subunits enhanced the anti-leukemic effects of riboflavin depletion in our screen. Our CRISPR-Cas9 screen also revealed, unexpectedly, that loss of iron-sulfur (Fe-S) cluster assembly factors enhanced the anti-leukemic effects of riboflavin depletion. Consistent with these findings, in a subsequent CRISPR-Cas9 screen in an AML cell line insensitive to RFK KO, NDOR1, a member of the cytosolic Fe-S cluster assembly machinery, scored as the top sensitizer to RFK loss. Fe-S clusters are ancient cofactors required for the function and stability of enzymes involved in electron transport and redox reactions. Indeed, global proteomics analysis in cells lacking RFK, or in riboflavin restricted media, showed a strong decrease in Fe-S cluster-dependent enzymes. We demonstrated that RFK KO induced a potent iron starvation response analogous to Fe-S cluster starvation, characterized by increased iron responsive element protein and transferrin receptor levels, with a concomitant decrease in the activity and stability of Fe-S cluster-containing enzymes such as aconitases. To explore perturbation of riboflavin metabolism as an anti-leukemic strategy, we took advantage of previous reporting of a correlation between reduced mitochondrial respiratory activity and sensitivity to BCL-2 inhibition. Consistent with our findings that perturbing riboflavin metabolism ablates oxidative phosphorylation, RFK KO or depletion of exogenous riboflavin strongly sensitized AML cell lines and cultured PDX cells to the BCL-2 inhibitor venetoclax. These findings were phenocopied using roseoflavin, a riboflavin antimetabolite, which was highly synergistic in killing AM
Year:
2024
Year:
2023
Collaborators (5)
Alexandra Forman
Massachusetts General Hospital
He Zhu
Research Scientist
University of Virginia
Lucy Merickel
Dana-Farber Cancer Institute
Yana Pikman
Boston Children's Hospital
Kimberly Stegmaier
Chair, Department of Pediatric Oncology
Dana-Farber Cancer Institute
Make your next move.
Prepare your application
Review drafts before you send them.